Source: Health Products Regulatory Authority (IE) Revision Year: 2023 Publisher: Opella Healthcare France SAS T/A Sanofi, 82 Avenue Raspail, 94250 Gentilly, France
Telfast 120 mg film-coated tablets.
| Pharmaceutical Form |
|---|
|
Film-coated tablet. Peach, modified capsule-shaped, film-coated tablet of 6.1 × 15.8 mm debossed with “012” on one side and a scripted “e” on the other side. |
Each tablet contains 120 mg of fexofenadine hydrochloride, which is equivalent to 112 mg of fexofenadine.
For the full list of excipients, see section 6.1.
| Active Ingredient | Description | |
|---|---|---|
| Fexofenadine |
Fexofenadine is a non-sedating H1 antihistamine. Fexofenadine is a pharmacologically active metabolite of terfenadine. |
| List of Excipients |
|---|
|
Tablet core: Microcrystalline cellulose Film coat: Hypromellose |
PVC/PE/PVDC/Al or PVC/PVDC/Al blisters, packaged into cardboard boxes. 2(sample only), 7, 10, 15, 20, 30, 50, 100 and 200 (as 10x20) tablets per package.
Not all pack sizes may be marketed.
Opella Healthcare France SAS T/A Sanofi, 82 Avenue Raspail, 94250 Gentilly, France
PA23180/003/002
Date of first authorisation: 11 November 1997
Date of last renewal: 20 July 2020
| Drug | Countries | |
|---|---|---|
| TELFAST | Australia, Cyprus, Germany, Spain, Finland, France, Hong Kong, Croatia, Ireland, Italy, Malta, Netherlands, New Zealand, Poland, Singapore, Tunisia, Turkey, United Kingdom, South Africa |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
